Provided by Tiger Fintech (Singapore) Pte. Ltd.

PIMCO Municipal Income Fund II

7.18
-0.0400-0.55%
Post-market: 7.180.00000.00%16:10 EDT
Volume:505.75K
Turnover:3.64M
Market Cap:477.42M
PE:-134.41
High:7.22
Open:7.19
Low:7.18
Close:7.22
52wk High:9.52
52wk Low:7.11
Shares:66.49M
Float Shares:66.49M
Volume Ratio:1.41
T/O Rate:0.76%
Dividend:0.47
Dividend Rate:6.60%
EPS(TTM):-0.0534
EPS(LYR):-0.0534
ROE:0.09%
ROA:2.48%
PB:0.84
PE(LYR):-134.41

Loading ...

Bank of America Corp Acquires Common Shares in PIMCO Municipal Income Fund II

Reuters
·
Jul 08

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

GlobeNewswire
·
May 02

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

GlobeNewswire
·
Apr 10

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

GlobeNewswire
·
Apr 07

PIMCO Closed-End Funds Announce Proposed Reorganizations

GlobeNewswire
·
Apr 05

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

PR Newswire
·
Apr 04

UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS

PR Newswire
·
Mar 13

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

GlobeNewswire
·
Mar 07

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

GlobeNewswire
·
Mar 04

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

GlobeNewswire
·
Feb 27

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

GlobeNewswire
·
Feb 04

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma

Business Wire
·
Jan 17